Trials / Withdrawn
WithdrawnNCT04334629
LIBERATE Trial in COVID-19
Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- King's College London · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibuprofen | Lipid ibuprofen 200 mg |
Timeline
- Start date
- 2020-05-26
- Primary completion
- 2021-05-25
- Completion
- 2021-09-25
- First posted
- 2020-04-06
- Last updated
- 2023-07-25
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04334629. Inclusion in this directory is not an endorsement.